Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2 Mln
P/E Ratio
0
P/B Ratio
0.41
Industry P/E
--
Debt to Equity
0
ROE
-8.42 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-89.64 Mln
EBITDA
$-168.55 Mln
Net Profit
$-10,133,143.46 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Qualigen Therapeutics (QLGN)
| -13.54 | 13.04 | -12.92 | -77.11 | -77.15 | -74.52 | -- |
|
BSE Sensex
| 1.72 | 3.50 | 4.95 | 8.90 | 11.18 | 21.04 | 11.14 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Qualigen Therapeutics (QLGN)
| -84.45 | -57.33 | -87.95 | -64.45 | -28.72 | -71.85 | -81.62 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.31 | 9,973.38 | 20.56 | 23.13 | |
| 279.03 | 8,956.07 | 23.48 | 58.42 | |
| 25.58 | 9,559.25 | -- | -28.77 | |
| 101.91 | 10,030.35 | 30.81 | 14.16 |
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company's lead program is QN-302, an investigational small... molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California. Address: 5857 Owens Avenue, Carlsbad, CA, United States, 92008 Read more
President, COO, CEO & Chairman
Mr. Michael S. Poirier
President, COO, CEO & Chairman
Mr. Michael S. Poirier
Headquarters
Carlsbad, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Qualigen Therapeutics Inc (QLGN) stood at $ 7 Mln as on 30-Sep-24
The share price of Qualigen Therapeutics Inc (QLGN) is $3.64 (NASDAQ) as of 22-Apr-2025 14:29 EDT. Qualigen Therapeutics Inc (QLGN) has given a return of -77.15% in the last 3 years.
Qualigen Therapeutics Inc (QLGN) has a market capitalisation of $ 2 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Qualigen Therapeutics Inc (QLGN) is 0.41 times as on 21-Apr-2025, a 82% discount to its peers’ median range of 2.25 times.
Since, TTM earnings of Qualigen Therapeutics Inc (QLGN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Qualigen Therapeutics Inc (QLGN) and enter the required number of quantities and click on buy to purchase the shares of Qualigen Therapeutics Inc (QLGN).
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California. Address: 5857 Owens Avenue, Carlsbad, CA, United States, 92008
The CEO & director of Mr. Michael S. Poirier. is Qualigen Therapeutics Inc (QLGN), and CFO & Sr. VP is Mr. Michael S. Poirier.
There is no promoter pledging in Qualigen Therapeutics Inc (QLGN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Qualigen Therapeutics Inc. (QLGN) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Qualigen Therapeutics Inc (QLGN) was $0 Mln.
$0.11
(
